|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION MAY BE ASSOCIATED WITH INCREASED RISK OF BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED PROTHROMBIN TIME, WITH OR WITHOUT CLINICAL BLEEDING
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED ANTICOAGULANT EFFECTS ; THESE EFFECTS MAY BE PRONOUNCED IN THE ELDERLY
|
CO-ADMINISTRATION HAS RESULTED IN INCREASED ANTICOAGULANT EFFECTS ; THESE EFFECTS MAY BE PRONOUNCED IN THE ELDERLY
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
CO-ADMINISTRATION WITH ANTIPLATELET AGENTS MAY BE ASSOCIATED WITH AN INCREASE IN BLEEDING.
|
HYALURONIDASE ACTION IS POTENTIATED BY THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|
NSAIDS CONCURRENT ADMINISTRATION MAY INCREASE THE RISK OF HAEMORRHAGE
|